Osaka, Japan and Cambridge, Massachusetts, August 5, 2026
Takeda has received U.S. Food and Drug Administration approval for ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist for the treatment of adults with narcolepsy type 1 (NT1), marking a major advance in the treatment of the rare chronic neurological disorder. ORZEYFUL is described as the first-in-class orexin treatment and the first and only medicine approved in the United States to address the underlying orexin deficiency associated with NT1, rather than focusing solely on individual symptoms. Narcolepsy type 1 is driven by loss of orexin signaling and can cause excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted nighttime sleep. Takeda estimates the condition affects approximately 120,000 people in the United States, highlighting the potential importance of a treatment designed around the fundamental biology of the disease.
ORZEYFUL Targets the Underlying Orexin Deficiency
Unlike therapies primarily intended to manage individual manifestations of narcolepsy, ORZEYFUL selectively stimulates OX2R to restore signaling associated with the orexin deficiency underlying NT1. Activation of orexin receptor 2 promotes wakefulness and reduces abnormal rapid eye movement sleep-like phenomena, including cataplexy, allowing the therapy to address a range of daytime and nighttime symptoms evaluated during its clinical development. The approval therefore introduces an important new therapeutic mechanism into narcolepsy care. As a first-in-class orexin receptor agonist, oveporexton also represents a significant milestone for Takeda’s broader neuroscience research strategy. The company is developing additional orexin agonists across multiple sleep-wake disorders and other conditions in which orexin biology may play an important role.
Phase 3 Studies Support FDA Approval
The FDA decision was supported by a comprehensive clinical development program that included the global Phase 3 FirstLight and RadiantLight studies. According to Takeda, the studies demonstrated statistically significant improvements across multiple dimensions of NT1, including excessive daytime sleepiness, cataplexy and health-related quality of life. Oveporexton was generally well tolerated, with a safety profile that remained consistent across clinical studies. The most commonly reported adverse reactions in Phase 3 studies included insomnia, urinary frequency, urinary urgency and excessive salivation. The prescribing information also includes precautions concerning creatine phosphokinase elevations and drug interactions involving CYP3A inhibitors and inducers. ORZEYFUL is contraindicated in patients taking strong CYP3A inhibitors. These safety considerations will be important as healthcare professionals assess appropriate patients for treatment following commercial availability.
Advertisement
Takeda Prepares ORZEYFUL for U.S. Commercial Launch
With FDA approval secured, Takeda is preparing for the U.S. launch of ORZEYFUL, although availability remains dependent on completion of the Drug Enforcement Administration scheduling process. The controlled-substance classification is currently under DEA review and is expected to be determined within approximately 90 days. Following scheduling, Takeda plans to make ORZEYFUL available to U.S. healthcare providers and adults with NT1 through a specialty pharmacy. The approval establishes a new therapeutic class in the U.S. narcolepsy market and provides an approach designed to address the biological deficiency driving NT1. It also represents a significant regulatory achievement for Takeda’s orexin research franchise, demonstrating how advances in understanding sleep-wake biology can translate into new medicines. As ORZEYFUL moves toward commercial availability, its first-in-class mechanism and Phase 3 clinical evidence position the medicine as a notable development in neuroscience, sleep medicine and rare neurological disease treatment.
Source: Takeda press release
